



**ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464**

January 21, 2016

Details

Published on Thursday, 21 January 2016 17:00

**Paris, France January 21st 2016** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced the acceptance of the abstract "Early Evidence of Antiviral Activity & Safety of ABX464 in HIV Treatment Naive Patients," as a late-breaking news presentation by the prestigious Conference on Retroviruses and Opportunistic Infections (CROI), to be held February 22-25, 2016 in Boston, Massachusetts, at the Hynes Convention Center.